MIA researchers feature on prestigious Highly Cited Researchers 2021 List
19 November 2021
Melanoma Institute Australia is proud to announce that MIA’s Co-Medical Directors, Professor Georgina Long AO and Professor Richard Scolyer AO, as well as MIA Faculty members Associate Professor Alex Menzies and Associate Professor Matt Carlino, and former Faculty member Professor Rick Kefford AM, have all been named on the annual Highly Cited Researchers™ 2021 list from Clarivate.
The highly anticipated annual list is the “who’s who” of the scientific elite from across the globe. It identifies the ‘One in 1,000’ Citation Elite – the researchers who demonstrated significant influence in their chosen field or fields through the publication of multiple highly cited papers during the last decade. Their names are drawn from the publications that rank in the top 1% by citations for field and publication year in the Web of Science™ citation index.
According to Clarivate, 6,602 researchers from more than 70 countries and regions have been recognized this year. Australia has narrowly overtaken Germany to come in fourth, with 332 researchers making the list- remarkable for a country of 25 million compared with Germany’s 83 million.
David Pendlebury, Senior Citation Analyst at the Institute for Scientific Information at Clarivate said:
‘It is increasingly important for nations and institutions to recognize and support the exceptional researchers who are driving the expansion of the world’s knowledge. This list identifies and celebrates exceptional individual researchers at Melanoma Institute Australia who are having a significant impact on the research community as evidenced by the rate at which their work is being cited by their peers. The research they have contributed is fuelling the innovation, sustainability, health and security that is key for our society’s future.’
Melanoma Institute Australia CEO Matthew Browne said the inclusion of four current members of MIA’s Faculty on the global list for the second year running was indicative of our standing on the world stage.
‘To have MIA researchers feature so prominently in the ‘who’s who’ of the world’s scientific elite shows the life-changing impact of our work not only in Australia but internationally,’ he said. ‘Under the leadership of our Co-Medical Directors, Professor Georgina Long AO and Professor Richard Scolyer AO, MIA continues to reach new heights and spearhead the world towards a cure for not only melanoma, but increasingly other complex skin cancers as well. On behalf of the entire MIA team, and our patients, their families and our wonderfully supportive community and donors, I extend my heartfelt congratulations to our four Faculty members named on the Highly Cited Researchers list.’
The full 2021 Highly Cited Researchers list and executive summary can be found online here.
Melanoma Institute Australia is affiliated with The University of Sydney
Early lymph node check is saving lives in melanoma patients
We are pleased to announce that A/Prof Anne Cust is the new President of the Australasian Epidemiological Association.
More than $3.5 million in competitive funding grants have been awarded to MIA's researchers.
The ESMO conference provided a platform for announcing a number of key melanoma research findings - including practice-changing research from MIA.
Australian researchers have successfully trialled a combination of new treatments to prevent melanoma from spreading to distant organs.
A new treatment that combines an antibody with a cancer-killing virus improves outcomes for patients with advanced melanoma, an international clinical trial has shown.
It feels like groundhog day - another reality TV show, another batch of blatantly sunburnt contestants.
Wouldn’t it be great if your doctor could know if you would respond to treatment before you even had it?
In our latest research update we showcase research in survival estimates, uncover biomarkers, and reveal practice-changing research in surgery and medical oncology.
Senior Clinical Trial Coordinators, like Sarah Lane, support melanoma patients throughout the clinical trial process.
Melanomas are often hard to differentiate from moles. But new technology is helping to improve accuracy of diagnosis.
We are excited to announce that SunSense will proudly be an official supporter of Melanoma Institute Australia. SunSense is an Australian, family owned business.
Five years ago Julie Randall was diagnosed with melanoma and was given months to live. The melanoma had spread throughout her body. The doctors said it was incurable and she’d be lucky if she survived the next nine months. Julie, a patient at Melanoma Institute Australia under Professor Georgina Long was placed on an experimental drug trial. To watch the entire program, visit 9now.com or click here.
Meet our latest Surgical Oncology Fellow, Eva Nagy, to find out more about life as a surgical oncologist, why she came to MIA and what she hopes to achieve.
Melanoma research at ASCO this year focussed on the more precise use of current treatments to ensure optimal treatment for each patient.
MIA recently demonstrated that reflectance confocal microscopy is a useful tool in the clinic to diagnose suspicious-looking lesions in the mouth.
New research is likely to change the way melanoma is managed in many patients by reducing the need for major surgery and its associated morbidity and cost.
Researchers from MIA will present their latest research findings to the world’s largest oncology conference in early June.